1) Assess and compare adherence to IV and subcut vedolizumab maintenance therapy in patients with IBD using a novel remote monitoring system. 2) Assess symptom response to vedolizumab post induction (week 6-8) and during maintenance therapy (week 26) using a novel remote monitoring system. 3) Assess time to response to vedolizumab during induction (weeks 0-6) using a novel remote monitoring system.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Millie Long
Medicine-Gastroenterology
Clinical or Medical
Observational
Stomach, Digestion and Gut Health
25-0886
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
